openPR Logo
Press release

Porphyria Treatment Market Detailed Study Analysis with Forecast by 2026 | ACON Laboratories, Bio-Rad Laboratories, Dahaner, Hoffmann-La Roche, Siemens AG, ARKRAY

05-27-2019 04:19 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Coherent Market Insights

Porphyria Treatment

Porphyria Treatment

Porphyria is an inherited rare disorder that affects the nervous system or skin and may cause abdominal pain. Cells of porphyria patients are unable to change body chemicals called porphyrins and its precursors into heme, the substance responsible for blood color. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the exact rates of porphyria are unknown and vary globally. For instance, porphyria cutanea tarda is most common in the U.S., and variegate porphyria is frequent in South America. Some porphyrias such as erythropoietic protoporphyria, hepatoerythropoietic porphyria, and congenital erythropoietic porphyria occur when an individual receives two abnormal genes, one from each parent. The chances of an individual passing the abnormal gene or genes to the next generation depends on the type of porphyria. Acute porphyrias affects the nervous system and abdomen. Its attacks develop over hours or days and can last up to several weeks. Cutaneous porphyrias affects the skin.

Ask For a Sample Copy of This Business Report: https://www.coherentmarketinsights.com/insight/request-sample/1706

According to the American Porphyria Foundation, acute porphyria affects around 1 to 2 individual per 100,000. High incidence rate was reported in South Africa and Sweden. The foundation promotes comprehensive care necessary for treating individuals with Porphyria. It promotes the disease awareness, reduce the stigma associated with porphyria through physician education, and provides support for those affected. The foundation also organized the Porphyria Awareness Week in April 2018, 21-28.

Porphyria Treatment Market Dynamics

The most common tests used for porphyrias diagnosis are measurements of substances such as porphyrin precursors and porphyrins, in blood plasma, red blood cells, feces, and urine. Measuring enzymes in cells and mutations in DNA is useful for confirmation and family studies. Though, no cure is available for porphyria, there is treatment for each type of the disease. Treatment depends on the type and severity of the disorder and can involve treating with heme, giving medicines to relieve the symptoms, or drawing blood. Drugs like Thorazine, Chlorpromazine, Panhematin and Hemin can be used to treat symptoms of porphyria. Panhematin (Recordati Rare Diseases) is used for treating acute porphyrias. It is a lyophilized form of alkaline heme that has to be reconstructed immediately before administration and should be infused into a large peripheral vein. As per American Porphyria Foundation, Panhematin is the only commercially available heme therapy in the U.S.

Porphyria Cutanea Tarda (PCT) is the most common and treatable form of porphyria and occurs, due to deficiency of the enzyme, uroporphyrinogen decarboxylase (UROD). PCT is a genetic disorder, however, some people have a genetic (autosomal dominant) deficiency of UROD that results in growth of PCT. Most people with the inherited enzyme deficiency remain latent and show no symptoms. Various environmental factors can impact the occurrence and severity of symptoms of porphyria. Smoking, alcohol, change in hormones levels, stress, certain drugs, and dieting or fasting can trigger the signs and symptoms of some forms of porphyrias. Moreover, exposure to sunlight severely damages the skin of people with cutaneous porphyrias. However, low incidence rates of porphyria can negatively impact the porphyria treatment market

Porphyria Treatment Market Taxonomy

On the basis of drugs, the porphyria treatment market is segmented into:
Thorazine
Chlorpromazine
Panhematin
Hemin
Others

Porphyria treatment Market Regional Insights

Regional segmentation of porphyria treatment market by Coherent Market Insights includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America and Europe are expected to generate significant revenue share in the porphyria treatment market, owing to high presence of major industry players launching new products and conducting R&D for novel product development. For instance, in April 2018, Alnylam Pharmaceuticals, the leading RNAi therapeutics company, presented new results from the Phase 1 and Phase 1/2 open-label extension (OLE) studies of givosiran (RNAi therapeutic) targeting aminolevulinic acid synthase 1 (ALAS1) for the treatment of acute hepatic porphyrias. These results were presented at the European Association for the Study of the Liver (EASL), France.

Porphyria Treatment Market Competitive Landscape

Key players operating in the porphyria treatment market include ACON Laboratories, Inc., Bio-Rad Laboratories, Inc., Dahaner, Hoffmann-La Roche Ltd, Siemens AG, ARKRAY, Inc., and Sysmex Corporation. Industry players are working towards development of new treatments for the disease.

Download The PDF Brochure: https://www.coherentmarketinsights.com/insight/request-pdf/1706

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr.Shah
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Porphyria Treatment Market Detailed Study Analysis with Forecast by 2026 | ACON Laboratories, Bio-Rad Laboratories, Dahaner, Hoffmann-La Roche, Siemens AG, ARKRAY here

News-ID: 1754756 • Views: 404

More Releases from Coherent Market Insights

Rx Medical Food Market 2020 - 2026 | Market Dynamics By Top Players Abbott Labor …
The Rx Medical Food Market is expected to have a highly positive outlook for the next eight years 2019-2026. This Research Reports emphasizes on key industry analysis, market size, Share, growth and extensive industry dynamics with respect to with respect to drivers, opportunities, pricing details and latest trends in the industry. The global Rx Medical Food Market analysis further provides pioneering landscape of market along with market augmentation history and key
Patient Flow Management Solutions Market 2020 - 2026 | Industry Insights by Top …
The Patient Flow Management Solutions Market is expected to have a highly positive outlook for the next eight years 2019-2026. This Research Reports emphasizes on key industry analysis, market size, Share, growth and extensive industry dynamics with respect to with respect to drivers, opportunities, pricing details and latest trends in the industry. The global Patient Flow Management Solutions Market analysis further provides pioneering landscape of market along with market augmentation history
Biosimilar Pipeline Analysis Market 2020 - 2026 | Revenue Opportunies By Top Pla …
The Biosimilar Pipeline Analysis Market is expected to have a highly positive outlook for the next eight years 2019-2026. This Research Reports emphasizes on key industry analysis, market size, Share, growth and extensive industry dynamics with respect to with respect to drivers, opportunities, pricing details and latest trends in the industry. The global Biosimilar Pipeline Analysis Market analysis further provides pioneering landscape of market along with market augmentation history and key
Human Microbiome Market 2020 - 2026 | In-depth Analysis by Top PlayersEnterome …
The Human Microbiome Market is expected to have a highly positive outlook for the next eight years 2019-2026. This Research Reports emphasizes on key industry analysis, market size, Share, growth and extensive industry dynamics with respect to with respect to drivers, opportunities, pricing details and latest trends in the industry. The global Human Microbiome Market analysis further provides pioneering landscape of market along with market augmentation history and key development involved

All 5 Releases


More Releases for Porphyria

Porphyria Therapeutics- Pipeline Analysis 2018, Clinical Trials & Results | Alny …
Porphyria is a group of disorders including cutaneous porphyria and acute porphyria. Cutaneous porphyria affects the skin while acute porphyria affects the nervous system. Porphyria cutanea tarda is the most common type of porphyria prevalent in the U.S. Download the sample report at: https://www.pharmaproff.com/request-sample/1043 The common symptoms of porphyria are abdominal pain, chest pain, increased blood pressure, increased heart rate, muscle weakness, cramping, blisters, itching, swelling, constipation, vomiting, mental disorders,
Porphyria Treatment Market Growth By 2026 Dahaner, Siemens AG, ARKRAY Inc, Sysme …
Porphyria is an inherited rare disorder that affects the nervous system or skin and may cause abdominal pain. Cells of porphyria patients are unable to change body chemicals called porphyrins and its precursors into heme, the substance responsible for blood color. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the exact rates of porphyria are unknown and vary globally. For instance, porphyria cutanea tarda is
Global Swedish Porphyria Industry Assesment report 2018-2025
Swedish porphyria is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinogen deaminase. It is the most common of the acute porphyrias. In 2018, the global Swedish Porphyria market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from 2018. In this study, 2017 has been considered as the base year
Global Swedish Porphyria Therapeutics Market 2018 Latest Supply, Future Demand, …
Swedish porphyria is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinogen deaminase. It is the most common of the acute porphyrias. In 2018, the global Swedish Porphyria Therapeutics market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from 2018. In this study, 2017 has been considered as the base
Global Acute Intermittent Porphyria Therapeutics Market Report 2018: Top Organaz …
Acute intermittent porphyria (AIP), also called Swedish porphyria, pyrroloporphyria, intermittent acute porphyria) is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinogen deaminase. It is the most common of the acute porphyrias. In 2018, the global Acute Intermittent Porphyria Therapeutics market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from
Acute Intermittent Porphyria Drugs Market: Global Industry Analysis Report 2018
Acute intermittent porphyria (AIP), also called Swedish porphyria, pyrroloporphyria, intermittent acute porphyria) is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinogen deaminase. It is the most common of the acute porphyrias. In 2018, the global Acute Intermittent Porphyria Drugs market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from